| (a) | by deleting the item “Acyclovir” and substituting the following item:| “Acyclovir; except in dermatological preparations containing not more than 5% of acyclovir”; |
|
|
| (b) | by inserting, immediately below the item “Almitrine; its salts”, the following item: |
| (c) | by inserting, immediately below the item “Atorvastatin; its salts”, the following item: |
| (d) | by deleting the item “Beclomethasone; its salts; its esters; theirs salts” and substituting the following item:| “Beclomethasone; its salts; its esters; their salts; except in nasal sprays containing not more than 0.05% of beclomethasone, calculated as its free base”; |
|
|
| (e) | by deleting the item “Budesonide; its salts” and substituting the following item:| “Budesonide; its salts; except in nasal sprays containing not more than 0.2% of budesonide”; |
|
|
| (f) | by inserting, immediately below the item “Cabimicina; its salts; its esters; their salts”, the following item: |
| (g) | by inserting, immediately below the item “Carvedilol”, the following item:| “Caspofungin; its salts”; |
|
|
| (h) | by inserting, immediately below the item “Cerivastatin; its salts”, the following item: |
| (i) | by deleting the item “Cimetidine; its salts” and substituting the following item:| “Cimetidine; its salts; except oral preparations containing not more than 100mg in solid dosage form, or 100mg/5ml in liquid dosage form, of cimetidine, calculated as its free base”; |
|
|
| (j) | by inserting, immediately below the item “Clindamycin; its salts; its esters; their salts”, the following item: |
| (k) | by inserting, immediately below the item “Daclizumab”, the following item: |
| (l) | by inserting, immediately below the item “Debrisoquine; its salts”, the following items: | Deferoxamine; its salts”; |
|
|
| (m) | by deleting the item “Domperidone” ; |
| (n) | by inserting, immediately below the item “Doxepin; its salts”, the following item: | “Doxofylline; its salts”; |
|
|
| (o) | by inserting, immediately below the item “Droperidol”, the following item: |
| (p) | by inserting, immediately below the item “Efavirenz”, the following item: |
| (q) | by inserting, immediately below the item “Etafedrine; its salts”, the following item: |
| (r) | by inserting, immediately below the item “Etomidate; its salts”, the following item: |
| (s) | by inserting, immediately below the item “Etoposide; its salts”, the following item: |
| (t) | by deleting the item “Famotidine” and substituting the following item:| “Famotidine; except oral preparations containing not more than 10mg of famotidine calculated as its free base”; |
|
|
| (u) | by inserting, immediately below the item “Feprazone”, the following item:| “Fexofenadine; its salts; its esters; their salts”; |
|
|
| (v) | by inserting, immediately below the item “Follicle stimulating hormone (FSH)”, the following item:| “Fondaparinux; its salts”; |
|
|
| (w) | by inserting, immediately below the item “Gadopentetic acid; its salts”, the following item: |
| (x) | by inserting, immediately below the item “Ganciclovir; its salts”, the following items:| Gatifloxacin; its salts; its isomers; its esters; their salts”; |
|
|
| (y) | by inserting, immediately below the item “Gemfibrozil; its salts; its esters and salts of such esters”, the following item: |
| (z) | by inserting, immediately below the item “Glutethimide; its salts”, the following item:| “Glyceryl trinitrate; except when contained in sublingual preparations or transdermal patches”; |
|
|
| (za) | by inserting, immediately below the item “Hexoestrol; its salts”, the following item:| “Human blood products; except when contained in diagnostic kits”; |
|
|
| (zb) | by deleting the item “Ibuprofen; except when contained in dermatological preparations” and substituting the following item:| “Ibuprofen; except in dermatological preparations, or oral preparations containing not more than 200mg in solid dosage form, or 100mg/5ml in liquid dosage form, of ibuprofen”; |
|
|
| (zc) | by inserting, immediately below the item “Ifosfamide”, the following item: |
| (zd) | by inserting, immediately below the item “Itraconazole”, the following item: |
| (ze) | by inserting, immediately below the item “Lepirudin”, the following item:| “Lercanidipine; its salts”; |
|
|
| (zf) | by inserting, immediately below the item “Levamphetamine; its salts”, the following item:| “Levetiracetam; its salts; its isomers; their salts”; |
|
|
| (zg) | by inserting, immediately below the item “Levonorgestrel”, the following item: |
| (zh) | by inserting, immediately below the item “Lonazolac; its salts”, the following item: |
| (zi) | by deleting the item “Luteinising hormone” and substituting the following items:| “Lumefantrine; its salts; its isomers; their salts |
|
|
| (zj) | by inserting, immediately below the item “Midazolam; its salts”, the following item:| “Midodrine; its salts; its isomers; their salts”; |
|
|
| (zk) | by deleting the item “Minoxidil; its salts; except in dermatological preparations containing not more than 2% of minoxidil” and substituting the following item:| “Minoxidil; its salts; except when contained in topical preparations”; |
|
|
| (zl) | by inserting, immediately below the item “Natamycin; its salts; its esters; their salts”, the following item: |
| (zm) | by inserting, immediately below the item “Nealbarbitone”, the following item: |
| (zn) | by deleting the item “Nicotine; its salts; its quarternary compounds; their salts; except when contained in transdermal patches” and substituting the following item:| “Nicotine; its salts; its quarternary compounds; their salts; except when contained in transdermal patches or inhalers”; |
|
|
| (zo) | by deleting the item “Omeprazole; its salts” and substituting the following item: | “Omeprazole; its salts; its isomers; their salts”; |
|
|
| (zp) | by inserting, immediately below the item “Orphenadrine; its salts”, the following item:| “Oseltamivir; its salts”; |
|
|
| (zq) | by inserting, immediately below the item “Pargyline; its salts”, the following item: |
| (zr) | by deleting the item “Piroxicam” and substituting the following item:| “Piroxicam; except when contained in preparations intended for external application only”; |
|
|
| (zs) | by inserting, immediately below the item “Quinine; its quarternary compounds, their salts”, the following item: |
| (zt) | by inserting, immediately below the item “Rabeprazole; its salts; its esters and ethers; their salts”, the following item:| “Radioactive iodine, salts of; when contained in preparations intended for the treatment of human ailments”; |
|
|
| (zu) | by deleting the item “Ranitidine; its salts” and substituting the following items:| “Ranitidine; its salts; except oral preparations containing not more than 75mg in solid dosage form, or 150mg/10ml in liquid dosage form, of ranitidine, calculated as its free base |
|
|
| (zv) | by inserting, immediately below the item “Reserpine”, the following item:| “Residronic acid; its salts”; |
|
|
| (zw) | by inserting, immediately below the item “Sertraline; its salts”, the following item:| “Sibutramine; its salts”; |
|
|
| (zx) | by inserting, immediately below the item “Simvastatin”, the following item: |
| (zy) | by deleting the item “Sodium cromoglycate” and substituting the following item:| “Sodium cromoglycate; except ophthalmic or nasal preparations containing not more than 2% of sodium cromoglycate”; |
|
|
| (zz) | by inserting, immediately below the item “Streptozocin”, the following item:| “Strontium [89Sr], salts of; when contained in preparations intended for the treatment of human ailments”; |
|
|
| by inserting, immediately below the item “Teicoplanin”, the following item:| “Telithromycin; its salts”; |
|
|
| by inserting, immediately below the item “Temazepam”, the following items: |
| by deleting the item “Terbinafine; its salts” and substituting the following item:| “Terbinafine; its salts; except dermatological preparations containing not more than 1% of terbinafine, calculated as its free base”; |
|
|
| by inserting, immediately below the item “Thyroxine; its salts”, the following item:| “Tiagabine; its salts; its esters; their salts”; |
|
|
| by inserting, immediately below the item “Tinzaparin; its salts”, the following item: |
| by inserting, immediately below the item “Trastuzumab”, the following item: |
| by deleting the item “Triamcinolone; its salts” and substituting the following item:| “Triamcinolone; its salts; except preparations containing not more than 0.1% of triamcinolone acetonide in orabase”; |
|
|
| by deleting the item “Ubidecarenone (Co-enzyme Q10)”; |
| by inserting, immediately below the item “Verapamil; its salts”, the following item:| “Verteporfin; its salts; its isomers; their salts”; and |
|
|
| by inserting, immediately below the item “Zipeprol; its salts”, the following items:| Zolendronic acid; its salts”. |
|
[G.N. Nos. S 632/98; S 51/99; S 177/99; S 279/99; S 68/2000; S 238/2001] |